MATTHEW WIEDUWILT (SAN DIEGO)
NEW ALL DRUGS
The advent of targeted therapies for Ph-positive acute lymphoblastic leukemia (ALL) and more recently
Ph-negative ALL has transformed care and improved outcomes for adults with newly-diagnosed and
relapsed ALL. The aim of this talk is to present current data with newly-approved and investigational
agents alone or in rational combinations. In addition, ongoing trials of new drugs and drug
combinations will be discussed.
